Literature DB >> 16711316

Significant absorption of oral vancomycin in a patient with clostridium difficile colitis and normal renal function.

Sangita Aradhyula1, Farrin A Manian, Saad A S Hafidh, Saqib S Bhutto, Martin A Alpert.   

Abstract

Orally-administered vancomycin is poorly absorbed in most patients, usually producing minimal or subtherapeutic serum concentrations. Bowel inflammation may enhance absorption of oral vancomycin, particularly in those with renal failure. A 77-year-old female with Clostridium difficile (C difficile) colitis and normal renal function was treated with high doses of oral vancomycin and achieved serum concentrations in the therapeutic range. To our knowledge, this is the first report of a patient with C difficile colitis and normal renal function to develop therapeutic serum concentrations following oral administration of vancomycin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16711316     DOI: 10.1097/01.smj.0000216477.06918.a3

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  11 in total

1.  A Prospective Pilot Study on the Systemic Absorption of Oral Vancomycin in Children With Colitis.

Authors:  James W Antoon; Margaret Hall; Diana Metropulos; Michael J Steiner; Ravi Jhaveri; Jacob A Lohr
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Sep-Oct

Review 2.  Does oral vancomycin use necessitate therapeutic drug monitoring?

Authors:  Nevio Cimolai
Journal:  Infection       Date:  2019-11-11       Impact factor: 3.553

3.  Oral Absorption of Enteral Vancomycin in a Child with Clostridium difficile Colitis and Renal Impairment.

Authors:  Adam Wood; Katie Wassil; Elisa Edwards
Journal:  J Pediatr Pharmacol Ther       Date:  2013-10

Review 4.  Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.

Authors:  Karl Weiss; Robin L Allgren; Sarah Sellers
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

5.  Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.

Authors:  D N Gerding; D W Hecht; T Louie; C E Nord; G H Talbot; O A Cornely; M Buitrago; E Best; S Sambol; J R Osmolski; H Kracker; H H Locher; P Charef; M Wilcox
Journal:  J Antimicrob Chemother       Date:  2015-10-03       Impact factor: 5.790

6.  Enhanced oral bioavailability of vancomycin in rats treated with long-term parenteral nutrition.

Authors:  Keizo Fukushima; Akira Okada; Yoriko Hayashi; Hideki Ichikawa; Asako Nishimura; Nobuhito Shibata; Nobuyuki Sugioka
Journal:  Springerplus       Date:  2015-08-22

7.  Oral vancomycin desensitisation to treat Clostridium difficile infection in a vancomycin allergic patient.

Authors:  Shanti Mahabir; Ren Yik Lim; Fidelma Fitzpatrick; Colm Magee; Mary Keogan
Journal:  World Allergy Organ J       Date:  2013-09-30       Impact factor: 4.084

8.  Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection.

Authors:  Jieun Kim; Heejung Kim; Hyun Ju Oh; Hyung Sun Kim; Youn Jee Hwang; Dongeun Yong; Seok Hoon Jeong; Kyungwon Lee
Journal:  Ann Lab Med       Date:  2017-01       Impact factor: 3.464

9.  The Effects of Fasting and Massive Diarrhea on Absorption of Enteral Vancomycin in Critically Ill Patients: A Retrospective Observational Study.

Authors:  Takehiko Oami; Noriyuki Hattori; Yosuke Matsumura; Eizo Watanabe; Ryuzo Abe; Taku Oshima; Waka Takahashi; Shingo Yamazaki; Tatsuya Suzuki; Shigeto Oda
Journal:  Front Med (Lausanne)       Date:  2017-06-08

10.  An elderly woman with 'Red Man Syndrome' in association with oral vancomycin therapy: a case report.

Authors:  Phillippa Bailey; Henry Gray
Journal:  Cases J       Date:  2008-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.